bristol post steadi fourth-quart result close
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
adept partnership acquisit bristol-my squibb
built strong portfolio drug robust pipelin strategi
seen recent larg acquisit celgen net
firm excel pipelin strong entrench blood
cancer believ strong overal pipelin help support
wide moat steadi growth potenti
bristol creat strong pipelin brought partner
share develop cost diversifi risk clinic
regulatori failur believ cardiovascular partnership
repres one import partnership manag
blockbust potenti eliqui atrial fibril
bristol discov drug intern like strateg
partner decis move reduc risk lower
develop market cost
within pipelin bristol astut acquisit medarex help
cancer
immunotherapi yield sever major blockbust
compound bristol cancer drug opdivo hold potenti
revolution cancer treatment drive multi-billion-dollar
sale annual base solid efficaci combin potenti
drug strong price power howev competit
merck keytruda like limit bristol opdivo segment
market includ lung cancer
bristol aggress reposit expand
challeng patent loss compani shed diabet
busi medic imag group wound-car divis
nutrit busi effort focu high-margin
specialti drug group recent move acquir celgen move
bristol significantli specialti pharmaceut
segment market celgen drug larg target cancer
tend area strong drug price power
help bristol maintain drug price abil time
govern privat payer push back drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
bristol-my squibb discov develop market drug variou
indic cardiovascular oncolog immun disord key
focu bristol immuno-oncolog firm lead drug
develop unlik diversifi peer bristol exit
sever nonpharmaceut busi focu brand specialti drug
tend support strong price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
close celgen acquisit feb
bristol report fourth-quart result larg
line expect dont expect major
chang fair valu estim continu view
stock fairli valu base strong outlook
pipelin drug heavi patent loss
next five year look appropri valu
market also balanc outlook new drug
mitig patent loss support wide moat rate
firm
bristol integr celgen acquisit well
expect strong growth next two year led
cardiovascular drug eliqui blood cancer drug revlimid
expect eliqui continu gain share older
less effect warfarin still total
share market also revlimid continu
grow base longer durat treatment like gain
front-lin set global bristol key drug
opdivo like slightli fall due shrink
market potenti lung cancer patient continu shift
merck keytruda strong data first-lin
set expect opdivo gain new indic
first-lin lung cancer set return
drug growth addit expect rel
stabl sale opdivo renal cancer melanoma
 drive half current sale
near-term growth look solid gener pressur
intensifi earli stagger gener entri
revlimid close expect sale new
pipelin drug help mitig pressur expect
teva alvogen begin partial gener revlimid launch
earli increas full launch base
settlement howev expect new drug launch
myeloma drug help off-set gener
addit look outlook bristol
environment social govern len follow
celgen acquisit believ bristol larg well
posit portfolio drug bristol
price posit aspect esg includ legal
issu pleas see recent healthcar observ
esg risk affect moat valuat pharma
morningstar sustainalyt offer complementari
slightli lower bristol fair valu estim
base industri review potenti
litig cost factor discount
cash flow model longer durat regard
celgen acquisit believ deal creat valu
focus oncolog therapeut area overlap
billion annual cost synergi expect
major sg like commerci overlap
overhead make deal posit strateg also
celgen deal diversifi bristol oncolog portfolio
think reduc risk around signific number
late-stag immuno oncolog readout bristol given
bristol
launch
immuno-oncolog drug larger import
indic first-lin nsclc catch
combin treatment import despit
increas challeng larg nsclc market bristol
remain well-posit melanoma renal cancer
although compani face sever patent loss
next year continu strong convict
pipelin expand celgen acquisit led
opdivo potenti significantli alter
treatment paradigm sever major cancer set
project drug reach risk-adjust peak sale close
billion also eliqui cardiovascular diseas
continu grow despit alreadi develop
major blockbust base lead efficaci solid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rate key factor affect scenario analysi
includ degre success brand drug pipelin
along magnitud competit pressur
current market drug opdivo biggest driver
valuat far rang outcom drug drive
signific portion chang valuat
differ scenario lastli ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
base wide line-up patent-protect drug
entrench salesforc economi scale bristol
firm price drug level translat superior
return invest capit compar cost
particularli cancer drug area focu bristol
patent also provid bristol ampl time bring
forward next gener new drug addit
sever bristol current market drug biolog
creat addit hurdl gener firm cost
develop market biosimilar much higher
typic gener small molecul mani
entrench salesforc enabl compani partner
smaller drug compani gain access extern
creat drug augment intern drug-develop
effort addit bristol sheer size gener
strong stabl cash flow requir fund
approxim million need averag bring
new drug market
major patent cliff time period bristol
competit advantag stabil moat trend
stabil result combin fewer upcom
patent loss combin stronger pipelin
pipelin side bristol first-mov advantag
look whole compani expect averag
annual earn per share growth next five year
help celgen acquisit expect margin
expand high margin celgen drug fold
bristol portfolio high royalti rate paid eliqui
weigh gross margin firm longer
term expect earn fall begin
time period gener pressur key drug revlimid
eliqui emerg
inelast product portfolio
larg base low volatil cash flow
divers
bristol-my uncertainti medium higher
pharma peer group partli high product
bull case probabl
estim rel base case scenario analysi
show moder varianc henc medium uncertainti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
immuno-oncolog set set sever major
blockbust carri high margin
patent protect well next decad project
immuno-oncolog drug off-set patent
loss next three year addit bristol
late-stag pipelin exclus focus unmet medic
need specialty-car indic area debilit
lethal diseas pipelin focu help increas
research develop product fight back
increasingli risk-avers food drug
administr well increas reluct
part insur compani govern payer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
obristol growth prospect focus new cancer
indic opdivo cardiovascular drug eliqui
hold lead efficaci data within atrial
oth oncolog drug opdivo hold potenti
radic shift treatment paradigm sever
cancer indic result peak sale
billion annual
omor half bristol late-stag pipelin focus
immunolog cancer -- indic
fda aggress approv drug typic
oth acquisit celgen bring gener competit
cancer drug revlimid set major
owe believ larg portion bristol valuat tie
cancer drug opdivo could amplifi
neg impact stock clinic data poor
competitor report superior data opdivo
obristol recent move acquir celgen add
signific debt could becom challeng
repay competit strengthen key drug
price pressur increas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bristol carri fairli solid financi structur
debt/ebitda project close time howev
recent move acquir celgen expect
debt/ebitda reach time expect
metric fall bristol like pay
debt fairli quickli follow acquisit bristol
cashflow combin celgen cashflow put
firm solid financi foot worst
patent loss begin time period
bristol increas focu brand drug sell
unrel busi line elev exposur
patent loss increas brand drug focu
rais compani depend pipelin
result higher sale volatil observ
diversifi peer addit compani expos
risk face entir pharmaceut group includ
gener threat decreas price power owe
managed-car constraint product liabil case
product-specif standpoint believ compani
largest pipelin risk surround immunotherapi drug
could develop major blockbust fail
market depend clinic data risk
competitor merck roch take market
share immunotherapi rise compani
catch particularli combin therapi lastli
recent move acquir celgen add financi risk due
larg amount debt need financ deal overal
view compani uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
follow relinquish ceo post lamberto
andreotti giovanni caforio took
ceo view success plan natur progress
andreotti year old transit occur
decad experi pharmaceut industri
doctor caforio bring strong skill set top
posit join bristol caforio
know compani well import
firm fold celgen acquisit
stewardship front rate current manag
standard sever acquisit medarex
excel use capit deal like inhibitex
amylin repres overpay asset firm
largest acquisit celgen look like good use capit
increas fair valu estim follow
deal announc also posit side bristol
aggress cut cost adapt scale
follow patent loss believ help open
capit reinvest busi
cut cost bristol still provid signific fund
toward research develop effort key
creat next gener drug support high
return invest capit
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
bristol report solid data support recent
bristol report solid data weekend conjunct
annual american societi hematolog
meet late-stag drug liso-cel lymphoma
myeloma larg line
expect dont expect major chang
fair valu estim follow recent close
acquisit celgen support data around
celgen pipelin drug help reinforc bristol decis
acquir firm strong data pipelin
safeti data liso-cel look differenti versu
compet drug efficaci drug look solid
potenti less differenti safeti side liso-cel
shown profil look much toler
market drug novarti kymriah gilead
yescarta strong safeti liso-cel enabl
outpati usag drive usag drug
rel compet drug carri much toxic
file drug approv year project peak
annual sale billion
bristol also report solid efficaci data
manag safeti profil myeloma potenti
first car-t cell therapi focus bcma b-cell matur
antigen look like signific new drug treat
patient refractori set bristol expect file
first half also bristol hold sever
earlier-stag drug similar mechan action
includ t-cell engag earli data
support potenti conveni off-the-
shelf therapi model billion annual sale
portfolio bcma drug despit tough competit
landscap includ glaxo johnson johnson
continu view bristol lead posit regard
bcma market share gain next five year
complet review new blood cancer drug
includ market share gain detail clinic result
pleas see report immuno-oncolog beyond
car-t bispecif strategi support drug compani
moat trend valuat
bristol post steadi third quarter led eliqui
celgen deal set close year-end oct
slightli ahead expect dont expect
major chang fair valu estim base minor
out-performance despit stock recent runup still
view bristol under-valued market fulli
appreci firm pipelin includ celgen
pipelin
larg focus oncolog
immunolog area typic hold strong price power
strong combin pipelin solid entrench
immuno-oncolog reinforc wide moat rate
quarter total sale increas oper led
cardiovascular drug eliqui offset matur
product declin deceler growth immuno-
oncolog drug opdivo expect trend continu
eliqui look well posit continu take
share older drug warfarin also opdivo like fall
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
number patient avail second-
line non-small-cel lung cancer market shrink
patient move first-lin segment merck
well posit expect bristol
combin opdivo plu yervoy gain approv first-
line nsclc base posit data checkmat
unless detail data show
significantli better data keytruda continu
believ bristol penetr
metastat nsclc market outsid nsclc expect
bristol immuno-oncolog platform perform well
melanoma renal cancer
bristol track close celgen acquisit year-
end believ deal strengthen firm pipelin
beyond immunolog drug addit
rel weak increas import celgen
inreb fedratinib myelofibrosi ozanimod multipl
sclerosi blood cancer drug liso-cel
complet review bristol celgen pipelin
secur
innov counter price gener
headwind acceler
bristol lung cancer data favor checkmat
merck lead look secur sep
bristol-my report posit final data part one
chemotherapi first-lin non-smal cell lung cancer
nsclc dont expect signific chang
fair valu base data continu view bristol
under-valued acquisit celgen pipelin
fulli appreci market also continu
expect bristol focu oncolog drug drive strong
price power reinforc compani wide moat
cross-trial comparison drawback efficaci
bristol combin opdivo plu yervoy checkmat
doesnt look well posit merck keytruda-
plu chemotherapi howev patient
express approxim three quarter
patient adamantli use chemotherapi especi
due neutropenia anemia side effect issu bristol
combin offer best altern bristol
data low expressor less express
look competit trial design may limit
inclus sub-seg data label also data
squamou patient also
look competit
nevertheless merck control first-mov
advantag lead efficaci data believ keytruda
gain close first-lin metastat nsclc
market follow roch tecentriq bristol
opdivo includ yervoy one last remain
studi patient popul bristol checkmat
read first-half studi
includ chemotherapi prime help patient
aggress form diseas addit
control crossov import studi
believ part reason merck keytruda shown
rel strong overal surviv data relat limit
amount crossov chemotherapi arm
beyond first-lin nsclc expect next wave
import immuno-oncolog data address earli stage
cancer adjuv neoadjuv earli stage lung
cancer alon project close billion annual sale
probabl weight estim
probabl success earli treatment set
complet overview adjuvant/neoadjuv lung
market immuno oncolog drug pleas see report
titl immuno-oncolog drug adjuv lung
frontier strengthen moat
bristol sale otezla fair price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
remain secur innov counter price gener
headwind acceler
bristol-my squibb divest psoriasi drug otezla
billion repres price close
fair valu estim drug expect
major impact fair valu estim moat
firm deal appeas anti-trust
concern regul pend acquisit
celgen bristol follow announc divest
bristol guid close celgen deal late
slightli ahead previou guidanc think
updat guidanc reason
surpris potenti ownership
bristol pipelin psoriasi drug bm celgen
otezla caus anti-trust concern feder trade
commiss bristol face fire sale price otezla
continu view stronger two
psoriasi drug expect drug reach market
asset combin sever pipelin
perspect otezla add support
near-term growth project three-year compound
growth rate drug along exclus
least longer market also
strong presenc understand psoriasi market
develop commerci enbrel
mean rel smooth transit market otezla
longer term expect take share
otezla base stronger efficaci seen earli stage
studi drug offer conveni oral
administr addit expect
take share biolog psoriasi drug base easier
oral dose versu inject superior efficaci
complet review outlook psoriasi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
